hs-CRP: the inflammation number, in context
A cheap marker of low-grade inflammation that adds a little to cardiovascular risk prediction — useful at the margins, not a diagnosis.
The quick answer
High-sensitivity CRP measures background inflammation and nudges your cardiovascular risk estimate up or down at the margins. It's most useful when a treatment decision is borderline. It's non-specific — infections, injury, and obesity raise it too — so read it as one input, not a verdict.
High-sensitivity C-reactive protein is one of those numbers that sits between genuinely useful and easily over-read. It measures low-grade systemic inflammation, and since atherosclerosis is partly an inflammatory process, a persistently elevated hs-CRP tracks with somewhat higher cardiovascular risk. The word doing the work there is somewhat.
What the evidence actually supports
The landmark result is the JUPITER trial. It took nearly 18,000 healthy people who had normal LDL but elevated hs-CRP and randomized them to a statin or placebo. The statin group had about 44% fewer first major cardiovascular events. That’s a real, important finding — but notice what it does and doesn’t say. It shows that people with high inflammation still benefit from a statin, even when their cholesterol looks fine. It does not show that hs-CRP is a thing you take a drug to lower for its own sake; the benefit came from the statin’s broader effects, and CRP was the tool that identified who to treat.
Where it helps, and where it misleads
As a standalone predictor, hs-CRP adds only modestly on top of a good risk calculator. Its real use is at the margins: when someone sits at intermediate calculated risk and the decision to start a statin is genuinely 50/50, a high hs-CRP can tip the reasoning toward treating. That’s a legitimate, guideline-recognized role.
The trap is its non-specificity. hs-CRP rises with any infection, recent injury, flare of an inflammatory condition, or simply higher body fat. A single high reading during a cold means nothing about your heart. If it’s checked at all, it should be measured when you’re well, ideally more than once, and always interpreted alongside the rest of your risk picture rather than as a verdict on its own.
The honest placement
hs-CRP lives low in the labs tier for a reason: for most people, it won’t change what happens next, because the foundational levers and the core cardiometabolic numbers already point the way. It earns its place only in that narrow band where the treatment decision is truly uncertain — and even there, it’s a nudge, not an answer.
Evidence, by outcome
Each claim carries its own grade. A strong grade on one outcome doesn't launder a weak one — read them separately.
In healthy people with normal LDL but elevated hs-CRP, a statin reduced first major cardiovascular events by roughly 44%. 1
The JUPITER trial (rosuvastatin) — a strong result for that specific population. It showed statins help high-CRP people, not that CRP itself must be 'treated.'
hs-CRP is a non-specific inflammation marker; on its own it adds only modestly to standard cardiovascular risk prediction. 1
Infection, injury, obesity, and other conditions all raise it. It's an adjunct to a risk calculator, not a standalone test.
Sources
- 1 Randomized trial
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER)
New England Journal of Medicine, 2008
Read the source pubmed.ncbi.nlm.nih.gov